November 4, 2025.
ORLANDO, FL — November 4, 2025 — Leads & Copy — Exousia Pro, Inc. (OTCPINK:MAJI) has achieved a significant technical milestone by successfully loading milk-derived exosomes with Cannabidiol (CBD) material, a pivotal advancement in oral drug delivery. The company’s scientists are encouraged by evidence that indicates the extraction process removes allergenic milk proteins, which could lead to a novel, non-allergenic delivery vehicle.
This success advances the Institutional Review Board (IRB) study, which will investigate and quantify the bioavailability of the loaded CBD material. The loading process will be offered to CBD manufacturers after analyzing the IRB study data.
Matt Dwyer, President of Exousia Pro, Inc., stated that the targeted loading de-risks the product pipeline and accelerates the timeline toward revenue generation.
Exousia Pro, Inc. confirms that all research and product development activities involve hemp-derived cannabinoids compliant with the 2018 U.S. Farm Bill.
Investor Relations can be contacted at ir@exousiapro.com.
Source: Exousia Pro, Inc.
